These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 25224804

  • 21. Evaluation of the inhibitory effects of telmisartan on drug-induced renin-angiotensin-aldosterone system activation in normal dogs.
    Konta M, Nagakawa M, Sakatani A, Akabane R, Miyagawa Y, Takemura N.
    J Vet Cardiol; 2018 Oct; 20(5):376-383. PubMed ID: 30126722
    [Abstract] [Full Text] [Related]

  • 22. Dose-response of benazepril on biomarkers of the classical and alternative pathways of the renin-angiotensin-aldosterone system in dogs.
    Sotillo S, Ward JL, Guillot E, Domenig O, Yuan L, Smith JS, Gabriel V, Iennarella-Servantez CA, Mochel JP.
    Sci Rep; 2023 Feb 15; 13(1):2684. PubMed ID: 36792677
    [Abstract] [Full Text] [Related]

  • 23. Evaluation of the effect of an angiotensin-converting enzyme inhibitor, alacepril, on drug-induced renin-angiotensin-aldosterone system activation in normal dogs.
    Sakatani A, Miyagawa Y, Takemura N.
    J Vet Cardiol; 2016 Sep 15; 18(3):248-254. PubMed ID: 27364087
    [Abstract] [Full Text] [Related]

  • 24. Pharmacodynamic assessment of diuretic efficacy and braking in a furosemide continuous infusion model.
    Adin D, Atkins C, Papich MG.
    J Vet Cardiol; 2018 Apr 15; 20(2):92-101. PubMed ID: 29483040
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Effect of benazepril and pimobendan on serum angiotensin-converting enzyme activity in dogs.
    King JN, Christinaz C, Strehlau G, Hornfeld J.
    J Vet Pharmacol Ther; 2018 Jun 15; 41(3):485-489. PubMed ID: 29392741
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, Tsubakihara Y, Imai E, Shoji T.
    Hypertens Res; 2008 Jan 15; 31(1):59-67. PubMed ID: 18360019
    [Abstract] [Full Text] [Related]

  • 30. Comparison between the effects of torsemide and furosemide on the renin-angiotensin-aldosterone system of normal dogs.
    Potter BM, Ames MK, Hess A, Poglitsch M.
    J Vet Cardiol; 2019 Dec 15; 26():51-62. PubMed ID: 31809955
    [Abstract] [Full Text] [Related]

  • 31. Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure.
    Mentz RJ, Stevens SR, DeVore AD, Lala A, Vader JM, AbouEzzeddine OF, Khazanie P, Redfield MM, Stevenson LW, O'Connor CM, Goldsmith SR, Bart BA, Anstrom KJ, Hernandez AF, Braunwald E, Felker GM.
    JACC Heart Fail; 2015 Feb 15; 3(2):97-107. PubMed ID: 25543972
    [Abstract] [Full Text] [Related]

  • 32. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
    Tylicki L, Rutkowski P, Renke M, Larczyński W, Aleksandrowicz E, Lysiak-Szydlowska W, Rutkowski B.
    Am J Kidney Dis; 2008 Sep 15; 52(3):486-93. PubMed ID: 18423812
    [Abstract] [Full Text] [Related]

  • 33. Fibroblast growth factor 23 and the antiproteinuric response to dietary sodium restriction during renin-angiotensin-aldosterone system blockade.
    Humalda JK, Lambers Heerspink HJ, Kwakernaak AJ, Slagman MC, Waanders F, Vervloet MG, Ter Wee PM, Navis G, de Borst MH, NIGRAM Consortium.
    Am J Kidney Dis; 2015 Feb 15; 65(2):259-66. PubMed ID: 25278093
    [Abstract] [Full Text] [Related]

  • 34. Additive effects of a sodium chloride restricted diet and furosemide administration in healthy dogs.
    Lovern CS, Swecker WS, Lee JC, Moon ML.
    Am J Vet Res; 2001 Nov 15; 62(11):1793-6. PubMed ID: 11703026
    [Abstract] [Full Text] [Related]

  • 35. Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.
    Rao MS.
    J Assoc Physicians India; 2010 Feb 15; 58():102-8. PubMed ID: 20653151
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Is there a role for renin profiling in selecting chronic heart failure patients for ACE inhibitor treatment?
    Lim PO, MacFadyen RJ, Struthers AD.
    Heart; 2000 Mar 15; 83(3):257-61. PubMed ID: 10677399
    [Abstract] [Full Text] [Related]

  • 38. Effects of long-term treatment with enalapril or hydralazine on the renin-angiotensin-aldosterone system and fluid balance in dogs with naturally acquired mitral valve regurgitation.
    Häggström J, Hansson K, Karlberg BE, Kvart C, Madej A, Olsson K.
    Am J Vet Res; 1996 Nov 15; 57(11):1645-52. PubMed ID: 8915446
    [Abstract] [Full Text] [Related]

  • 39. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition.
    van de Wal RM, Plokker HW, Lok DJ, Boomsma F, van der Horst FA, van Veldhuisen DJ, van Gilst WH, Voors AA.
    Int J Cardiol; 2006 Jan 26; 106(3):367-72. PubMed ID: 16337046
    [Abstract] [Full Text] [Related]

  • 40. Breakthrough: a first-in-class virtual simulator for dose optimization of ACE inhibitors in translational cardiovascular medicine.
    Schneider BK, Ward J, Sotillo S, Garelli-Paar C, Guillot E, Prikazsky M, Mochel JP.
    Sci Rep; 2023 Feb 26; 13(1):3300. PubMed ID: 36843132
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.